Focused HIFU Non‑invasive TherapyTheraclion's specialization in high‑intensity focused ultrasound (HIFU) and ultrasound-based therapy for outpatient indications is a durable competitive strength. A narrow, proprietary technology focus can support differentiated products, clinical adoption, and specialized sales channels over multiple quarters.

Strong Free Cash Flow Growth TrendA 93.77% improvement in free cash flow growth indicates improving cash generation dynamics. While absolute operating and free cash flows remain negative, accelerating FCF growth can lengthen runway, reduce near‑term refinancing pressure, and support continued investment if the trend persists over subsequent quarters.

Alignment With Outpatient/minimally Invasive TrendTheraclion's product set targets outpatient, minimally invasive treatments (thyroid nodules, varicose veins), aligning with structural healthcare shifts toward lower‑cost, ambulatory care. This secular demand backdrop can expand the addressable market and ease adoption barriers over the medium term.

Bears Say

Severe Recent Revenue DeclineA roughly 75% revenue collapse materially weakens scale economics and undermines the business's ability to fund R&D, sales, and regulatory efforts. Sustained top‑line erosion makes margin recovery harder, increases dependency on external capital, and can erode market share over multiple reporting periods.

Negative Equity And Acute Solvency RiskNegative shareholders' equity and an extreme negative debt‑to‑equity metric reflect accumulated losses and capital shortfalls, signaling acute solvency risk. This structural balance sheet weakness limits financing options, raises refinancing/dilution risk, and impairs long‑term strategic flexibility.

Ongoing Negative Cash Flow And MarginsPersistently negative operating cash flow combined with deeply negative gross and net margins indicates the business isn't generating sustainable cash from core operations. This structural cash‑flow deficit necessitates external funding or dilution and constrains reinvestment for commercialization or product development.

TCLIF FAQ

What was Theraclion SA’s price range in the past 12 months?

Theraclion SA lowest stock price was $0.32 and its highest was $0.32 in the past 12 months.

What is Theraclion SA’s market cap?

Theraclion SA’s market cap is $42.79M.

When is Theraclion SA’s upcoming earnings report date?

Theraclion SA’s upcoming earnings report date is Apr 23, 2026 which is in 66 days.

How were Theraclion SA’s earnings last quarter?

Theraclion SA released its earnings results on Oct 29, 2025. The company reported -$0.063 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.063.

Is Theraclion SA overvalued?

According to Wall Street analysts Theraclion SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Theraclion SA pay dividends?

Theraclion SA does not currently pay dividends.

What is Theraclion SA’s EPS estimate?

Theraclion SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Theraclion SA have?

Currently, no data Available

What happened to Theraclion SA’s price movement after its last earnings report?

Theraclion SA reported an EPS of -$0.063 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Theraclion SA?

Currently, no hedge funds are holding shares in TCLIF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Theraclion SA

Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system. It offers SONOVEIN, a robotic solution for non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment and protects the patient's skin and optimizes the image quality. The company was founded in 2004 and is based in Malakoff, France.